Drug intelligence / Profile preview

NS-9

Development stage: Phase 1
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

NS-9 is a complex of poly-inosinate [poly(I)] and poly-cytidylate [poly(C)] in a cationic liposome. It was investigated in a first-in-human phase I pharmacokinetic trial for patients with liver metastases from solid tumors. The drug showed rapid elimination with a half-life ranging from 2.4 to 5.0 hours without accumulation after multiple doses. The maximum tolerated dose (MTD) was determined to be 0.2 mg/m².

Other names: polyinosinic-polycytidylic acidpoly I:C

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on NS-9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NS-9.

Explore the full profile